Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

The FDA's vaccine advisory committee meeting come less than a month after U.S. regulators authorized third Covid shots of Pfizer's vaccine.

U.S. moves closer to clearing Moderna and J&J Covid booster shots this week

Costco

Freeport-McMoRan

Merck

Pfizer

Procter & Gamble

Here's why long-term investors seeking defensive stocks to buy right now may want to consider these top seven options right now. The post 7 Defensive Stocks to Buy and Forget About In Times of Volatility appeared first on InvestorPlace.

7 Defensive Stocks to Buy and Forget About In Times of Volatility

AstraZeneca

Novavax

It'll likely push the revenue of vaccine victors even further.

What Do Mix-and-Match Doses Mean for Vaccine Stocks?

J&J (JNJ) submits data to the FDA to support an authorization for the booster dose of its single-shot COVID-19 vaccine.

J&J (JNJ) Seeks FDA Authorization for COVID-19 Booster Jab

BEERSE, Belgium, Oct. 6, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration with the KU Leuven Rega Institute and the KU Leuven Centre for Drug Design and Discovery (CD3), the publication of new preclinical data in the journal Nature showing that an early-stage compound with a novel mechanism of action could potentially treat all serotypes of dengue fever and provide a period of protection against acquiring the dengue virus. Janssen is now moving its dengue program into clinical development.

Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature

High-yield blue-chips can help you sleep well at night during market downturns, such as the 10% to 20% correction that might be coming in by October 18th. That's when the US is currently scheduled to default on its debts for the first time in history, which Moody's and virtually all economists think would trigger a horrific recession.

3 Reasons To Own Johnson & Johnson But Buy These 2 Faster-Growing High-Yield Blue-Chips Today

Xencor (XNCR) partners will J&J (JNJ) to develop and commercialize bispecific antibody candidates against B-cell malignancy. Resultantly, the stock gains.

Xencor (XNCR) Inks Deal With J&J for B-Cell Malignancy Treatment

AbbVie

Bristol-Myers

Gilead Sciences

GlaxoSmithKline

Eli Lilly

Sanofi

Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.

9 Big Pharmaceutical Stocks Sporting Stellar Yields

Johnson & Johnson (NYSE: JNJ) shares have lagged the S&P 500 in 2021, generating a year-to-date total return of just 3.6%. Johnson & Johnson has gotten plenty of headlines for its COVID-19 vaccine, but investors may be wondering just how much value is left in the pharma giant's stock?

Is Johnson & Johnson's Stock Overvalued Or Undervalued?

The company saw a "substantial increase" in immune response when booster of its COVID-19 vaccine was given six months after the first shot.

Johnson & Johnson seeks FDA emergency authorization for booster shot

Johnson & Johnson has submitted new data to the Food and Drug Administration in the hopes of securing emergency approval of its COVID-19 vaccine booster shot for people 18 and older.

Johnson & Johnson seeks emergency approval for COVID booster shot

The company has released data suggesting the second shot offers strong protection against Covid-19.

Johnson & Johnson Submits Booster Shot Data To FDA For Approval

Johnson & Johnson (NYSE: JNJ) has submitted data to the FDA seeking emergency use approval of its single-dose COVID-19 vaccine in individuals 18 years of age and older. The submission includes results from the Phase 3 ENSEMBLE 2 study that booster shot at two months provided 94% protection against symptomatic COVID-19 in the U.S.

Johnson & Johnson Seeks FDA Emergency Use Nod For COVID-19 Booster Dose

Johnson & Johnson JNJ, -0.78% said Tuesday it has submitted an amendment to the emergency use authorization it's seeking from the U.S. Food and Drug Administration for a booster shot of its COVID-19 vaccine with additional data showing it increased protection to 94% against moderate to severe or critical COVID-19 in the U.S.

J&J amends FDA EUA submission for COVID-19 booster with data showing 94% protection against moderate to severe illness

NEW BRUNSWICK, N.J., Oct. 5, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) announced it has submitted data to the U.S. Food and Drug Administration (FDA) to support use of a booster shot of the Johnson & Johnson COVID-19 vaccine in individuals 18 years of age and older.

Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine

Cisco Systems

Chevron

Goldman Sachs

Home Depot

JPMorgan Chase & Co

Coca-Cola

McDonald's

With uncertainty running high amid a return of volatility, the case for the best Dow dividend stocks is as strong as ever.

10 Dow Dividend Stocks Analysts Love the Most

Johnson & Johnson JNJ, -0.98% experimental respiratory syncytial virus (RSV) vaccine had an 80% efficacy rate against the virus, which can lead to bronchitis and pneumonia, according to new clinical data shared Saturday. It had a slightly lower efficacy rate of 70% when it comes to preventing symptomatic respiratory infections caused by the virus.

J&J to test experimental RSV vaccine in 23,000 people in Phase 3 clinical study

The company last month said it provided additional data to the FDA.

Johnson & Johnson to seek FDA authorization for booster shot this week, report says

Xencor

Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global licensing rights with Xencor Inc (NASDAQ: XNCR). The agreement covers Xencor's CD20/CD3 bispecific antibody plamotamab currently in Phase 1 testing against B cell malignancies.

JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody

Johnson & Johnson's (NYSE: JNJ) Janssen announced respiratory syncytial virus (RSV) vaccine candidate's efficacy as high as 80% in preventing severe infections in a mid-stage clinical trial. Related:  Pfizer Starts Late-Stage Trial For RSV Vaccine Candidate In Older Patients.

J&J's RSV Vaccine Candidate Shows 80% Efficacy In Older Adults

Johnson & Johnson (NYSE: JNJ) is reportedly planning to ask U.S. federal regulators to authorize a booster shot of its COVID-19 vaccine. What Happened: The U.S. Food and Drug Administration announced Friday that its expert advisory committee will meet on Oct. 15 to determine whether it should extend emergency use authorization for a booster shot of the COVID-19 vaccine developed by Johnson & Johnson's Janssen Biotech Inc. subsidiary.

Johnson & Johnson To Seek FDA Approval For COVID-19 Booster Shot: Report

J&J laid out new data on its respiratory syncytial virus vaccine over the weekend that one analyst says sets a new efficacy bar for the many big pharma firms competing to bring an RSV vaccine to market.

Johnson & Johnson Data on RSV Vaccines Raises Bar In industrywide Race

Buying Dividend Kings at fair prices is a one way to achieve strong total returns with lower volatility.

Johnson & Johnson Sell-Off: Is It a Buying Opportunity?

Apple

Microsoft

Exxon Mobil

These are some of the largest nominal payouts on Wall Street.

These 5 Dividend Stocks Pay $71 Billion a Year, Combined, to Their Shareholders

Innovative Industrial Properties

To enjoy a regular, stable income, dividend stocks are the way to go.

News for Johnson & Johnson Stock (JNJ)